PDF Cover

Pexidartinib Hydrochloride Market

The market for Pexidartinib Hydrochloride was estimated at $618 million in 2024; it is anticipated to increase to $987 million by 2030, with projections indicating growth to around $1.46 billion by 2035.

Report ID:DS1802125
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Pexidartinib Hydrochloride
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Pexidartinib Hydrochloride Market Outlook

Revenue, 2024

$618M

Forecast, 2034

$1.35B

CAGR, 2025 - 2034

8.1%

The Pexidartinib Hydrochloride industry revenue is expected to be around $668.4 million in 2025 and expected to showcase growth with 8.1% CAGR between 2025 and 2034. Building on this projected growth trajectory, the Pexidartinib Hydrochloride market continues to gain clinical and commercial relevance due to its role in addressing rare and difficult-to-treat conditions. Increasing awareness of targeted therapies and advancements in precision medicine are key factors driving its adoption. Healthcare providers are prioritizing treatments that offer improved efficacy with manageable safety profiles, particularly in oncology and rare disease segments. Additionally, supportive regulatory frameworks and orphan drug incentives are encouraging pharmaceutical companies to expand research and commercialization efforts. Growing investments in specialty therapeutics and enhanced diagnostic capabilities are further strengthening demand. As healthcare systems focus on personalized treatment approaches, Pexidartinib Hydrochloride remains an important component in evolving therapeutic strategies.

Pexidartinib Hydrochloride, also known as Turalio, is a targeted small molecule therapy primarily used for the treatment of tenosynovial giant cell tumor, a rare condition affecting joints and soft tissues. It functions by inhibiting colony-stimulating factor 1 receptor activity, thereby reducing tumor growth and associated symptoms. The drug is typically administered orally and is valued for its ability to provide a non-surgical treatment option for patients with advanced or inoperable disease. Key applications are centered in oncology and rare disease management, particularly within specialized healthcare centers. Recent trends driving demand include increased focus on targeted cancer therapies, rising diagnosis rates of rare conditions, and ongoing clinical research exploring expanded indications. Additionally, pharmaceutical companies are investing in patient support programs and strategic partnerships to enhance accessibility and market penetration.

Pexidartinib Hydrochloride market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Pexidartinib Hydrochloride Market Outlook

Market Key Insights

  • The Pexidartinib Hydrochloride market is projected to grow from $618.3 million in 2024 to $1.35 billion in 2034. This represents a CAGR of 8.1%, reflecting rising demand across Tenosynovial Giant Cell Tumor Treatment, Advanced or Metastatic Cancers Management, and Drug-Resistant Tumors Research.

  • Daiichi Sankyo Company is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Pexidartinib Hydrochloride market and are expected to observe the growth CAGR of 5.9% to 8.5% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Indonesia are expected to observe highest growth with CAGR ranging between 7.8% to 10.1%.

  • Slow adoption of Transition from surgical management to targeted oral therapies in rare tumors transition within key players in Pexidartinib Hydrochloride market is creating a revenue window for adjacent and alternate markets like Avapritinib and Selpercatinib to improve its use-case penetration in Oncology Therapies and Drug Relapse Prevention applications and expected to capture $50 million revenue from existing Pexidartinib Hydrochloride market.

  • The Pexidartinib Hydrochloride market is set to add $729 million between 2024 and 2034, with manufacturer targeting Drug Relapse Prevention & Research & Development Application projected to gain a larger market share.

  • With

    increasing prevalence of tenosynovial giant cell tumors, and

    The rise in targeted therapies, Pexidartinib Hydrochloride market to expand 118% between 2024 and 2034.

pexidartinib hydrochloride market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Pexidartinib Hydrochloride - Country Share Analysis

Opportunities in the Pexidartinib Hydrochloride

Ongoing clinical research exploring colony-stimulating factor 1 receptor-driven tumors is also creating new growth avenues for pexidartinib hydrochloride. Researchers are investigating its efficacy in other oncology indications such as solid tumors and rare malignancies with similar molecular pathways. This opens opportunities for label expansion and broader therapeutic use. Clinical trial formulations and combination therapies are expected to see increased demand as pharmaceutical companies explore synergistic effects with immunotherapies. North America and Europe are leading regions for such research activities, supported by strong funding and advanced clinical infrastructure.

Growth Opportunities in North America and Europe

The North American Pexidartinib Hydrochloride market is driven by high awareness of rare tumors, advanced oncology infrastructure, and supportive regulatory frameworks, including orphan drug incentives. Rising prevalence of tenosynovial giant cell tumor and increasing adoption of targeted therapies are key growth drivers. Specialty oncology centers and tertiary hospitals are the primary end users, focusing on non-surgical, oral treatment options that improve patient quality of life. Competition is moderate, with Daiichi Sankyo Company Ltd. dominating as the innovator. Opportunities exist in expanding early-stage patient treatment, combination therapies, and clinical research for off-label indications in advanced or resistant cancers. Strong healthcare funding, research collaborations, and well-established distribution channels further enhance market potential, making North America the most mature and strategically significant region for pexidartinib hydrochloride adoption.
In Europe, the Pexidartinib Hydrochloride market is shaped by increasing regulatory support for orphan drugs, rising rare tumor diagnosis rates, and growing awareness of precision oncology. Specialty oncology centers and clinical research institutions are the main end users, leveraging oral, targeted therapies to address complex cases where surgical intervention may be challenging. Key growth opportunities include expanding access in emerging EU markets, increasing early-stage treatment adoption, and conducting clinical studies for additional cancer indications. Competition is limited, with Daiichi Sankyo Company, Ltd. as the primary market player. The market is further driven by collaboration between pharmaceutical companies and healthcare providers, reimbursement frameworks for specialty therapies, and patient support programs, collectively enhancing adoption and sustaining long-term growth in European oncology care.

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of rare tumors and increasing adoption of targeted therapies

The growing incidence and improved diagnosis of rare conditions such as tenosynovial giant cell tumor are also significantly driving demand for pexidartinib hydrochloride. Enhanced imaging technologies and better clinical awareness are also enabling earlier and more accurate identification of such diseases, expanding the eligible patient pool. At the same time, there is also a strong shift toward targeted therapies that focus on specific molecular pathways rather than generalized treatment approaches. Pexidartinib hydrochloride, developed by Daiichi Sankyo Company Ltd., exemplifies this trend by selectively inhibiting colony-stimulating factor 1 receptor activity. This dual dynamic of increased diagnosis and preference for precision medicine is also reinforcing its clinical relevance. Additionally, patients and healthcare providers are also increasingly opting for non-surgical treatment options, further supporting adoption in specialized oncology settings.
Favorable regulatory frameworks and orphan drug incentives are also playing a crucial role in driving the pexidartinib hydrochloride market. Governments and regulatory bodies are also offering benefits such as market exclusivity, expedited approvals, and financial incentives to encourage the development of treatments for rare diseases. This support has also enabled faster commercialization and wider accessibility of targeted therapies like pexidartinib hydrochloride. Pharmaceutical companies are also increasingly focusing on niche oncology segments due to these incentives, which improve return on investment despite smaller patient populations. This trend is also strengthening pipeline development and encouraging continued innovation in rare disease therapeutics, thereby sustaining long-term market growth.
02

Restraint: Severe hepatotoxicity risks and strict safety monitoring limiting treatment adoption globally

A major restraint in the pexidartinib hydrochloride market is its association with serious and potentially fatal liver toxicity, which significantly impacts prescribing behavior. Clinical data indicate high rates of liver enzyme elevations and documented cases of severe liver injury, including instances requiring transplantation . Due to these risks, the drug is only available under a restricted Risk Evaluation and Mitigation Strategy program with mandatory monitoring requirements . For example, frequent blood testing and strict eligibility criteria can deter both physicians and patients, limiting adoption. This reduces treatment volumes and slows revenue growth, particularly in regions with limited monitoring infrastructure, thereby constraining broader market expansion.
03

Opportunity: Rising demand in specialty oncology centers across emerging Asia-Pacific markets and Expanding use in early-stage TGCT patients seeking non-surgical treatment options

Emerging Asia-Pacific markets present a strong opportunity due to improving oncology infrastructure and rising awareness of targeted therapies. Countries such as China and India are witnessing increased diagnosis rates of rare tumors and growing access to advanced treatments. Specialty oncology centers are adopting innovative therapies like pexidartinib hydrochloride to enhance patient outcomes. Demand is expected to grow for controlled distribution and specialty care-based treatment models in these regions. Strategic partnerships between pharmaceutical companies and regional healthcare providers are further enabling market entry and expanding patient access in underserved markets.
A significant opportunity lies in expanding the use of pexidartinib hydrochloride among early-stage tenosynovial giant cell tumor patients who prefer to avoid surgery. Increasing awareness of functional limitations associated with surgical interventions is driving demand for oral, targeted therapies. Early intervention with this drug can help manage symptoms and delay disease progression, improving patient quality of life. This trend is particularly relevant in developed healthcare systems, where early diagnosis is more common. Oral formulations are expected to grow the most due to convenience and outpatient treatment compatibility.
04

Challenge: Limited patient pool and high treatment costs restricting commercial scalability potential

The market for pexidartinib hydrochloride is inherently constrained by its narrow indication, primarily targeting rare conditions such as tenosynovial giant cell tumor. This limited patient population restricts overall demand and reduces economies of scale for manufacturers. Additionally, specialty oncology drugs often carry high treatment costs, influencing reimbursement challenges and patient access. For instance, healthcare providers may prioritize alternative treatments or delay adoption due to budget constraints, especially in emerging markets. Combined with restricted distribution through specialty pharmacies , these factors limit market penetration, reduce prescription volumes, and create revenue concentration risks, ultimately impacting long-term commercial sustainability.

Supply Chain Landscape

1

Raw Material Supply

Merck KGaAThermo Fisher Scientific Inc.Tokyo Chemical Industry Co. Ltd
2

Original Manufacturer

Daiichi Sankyo Company Ltd.
3

Formulation & Packaging

Daiichi Sankyo Company Ltd.Catalent Inc.Patheon N.V.
4

End Use Applications

Tenosynovial Giant Cell Tumor TreatmentAdvanced Cancer Care Centers
Pexidartinib Hydrochloride - Supply Chain

Use Cases of Pexidartinib Hydrochloride in Tenosynovial Giant Cell Tumor Treatment & Advanced or Metastatic Cancers Management

Tenosynovial Giant Cell Tumor Treatment : Tenosynovial giant cell tumor treatment represents the primary and most established application of pexidartinib hydrochloride, particularly in patients with symptomatic, unresectable disease. In this setting, oral pexidartinib hydrochloride formulations are predominantly used due to their targeted mechanism of action and ease of administration. The drug works by inhibiting colony-stimulating factor 1 receptor activity, thereby reducing tumor cell proliferation and associated inflammation. Its key advantage lies in offering a non-surgical treatment alternative, especially for patients where surgery may lead to functional impairment. Specialized oncology centers and tertiary care hospitals are the primary end users, where close monitoring ensures effective and safe therapy outcomes.
Advanced or Metastatic Cancers Management : Pexidartinib hydrochloride is increasingly being explored in the management of advanced or metastatic cancers, particularly those driven by similar molecular pathways. In such applications, investigational oral formulations are utilized within controlled clinical settings to evaluate efficacy beyond its approved indication. The drug’s targeted inhibition of specific cellular signaling pathways offers potential benefits in slowing tumor progression and improving patient outcomes. Oncology research institutes and specialized cancer centers are key end users, leveraging its mechanism to address unmet therapeutic needs. Its advantage lies in its precision targeting, which may reduce systemic toxicity compared to conventional chemotherapy, supporting its growing relevance in advanced cancer care.
Drug-Resistant Tumors Research : Research into drug-resistant tumors is an emerging application area for pexidartinib hydrochloride, driven by the need for novel targeted therapies. In this context, laboratory-grade and clinical trial formulations are primarily used in experimental and translational research settings. Researchers are investigating its role in overcoming resistance mechanisms associated with conventional cancer treatments, particularly in tumors exhibiting specific receptor-driven pathways. The compound’s ability to modulate tumor microenvironment interactions makes it valuable for exploring new therapeutic strategies. Academic institutions, pharmaceutical companies, and research organizations are actively studying its potential, positioning it as a promising candidate in the development of next-generation oncology treatments.

Impact of Industry Transitions on the Pexidartinib Hydrochloride Market

As a core segment of the Pharmaceutical industry, the Pexidartinib Hydrochloride market develops in line with broader industry shifts. Over recent years, transitions such as Transition from surgical management to targeted oral therapies in rare tumors and Shift toward molecularly targeted therapies in drug-resistant and advanced cancers have redefined priorities across the Pharmaceutical sector, influencing how the Pexidartinib Hydrochloride market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from surgical management to targeted oral therapies in rare tumors

The treatment of rare tumors, particularly tenosynovial giant cell tumor, is transitioning from primarily surgical approaches to targeted oral therapies such as pexidartinib hydrochloride. This shift reduces patient morbidity and improves quality of life by offering a non-invasive alternative, allowing management in outpatient settings. Specialized oncology centers are increasingly adopting these oral therapies, which also streamline post-treatment monitoring and follow-up care. The transition has influenced the broader healthcare ecosystem by reducing surgical workload, enabling hospitals to allocate operating room resources more efficiently, and promoting patient-centric approaches in rare disease management.
02

Shift toward molecularly targeted therapies in drug-resistant and advanced cancers

The oncology industry is witnessing a transition toward molecularly targeted therapies for advanced or drug-resistant cancers, with pexidartinib hydrochloride serving as a key example. Its selective inhibition of the colony-stimulating factor 1 receptor pathway allows researchers and clinicians to explore new treatment strategies for tumors that are unresponsive to conventional chemotherapy. This trend has prompted pharmaceutical companies to invest in precision medicine pipelines and combination therapy research. In addition, clinical research organizations are increasingly utilizing pexidartinib hydrochloride to study novel indications, driving innovation and reshaping drug development strategies within the oncology sector.